We are particularly interested in finding different strategies to stop or decrease HER2 signaling because HER2 targeting is not efficient in pancreatic cancer [17], and MUC4, which is not expressed on normal healthy pancreas, is neoexpressed very early during pancreatic carcinogenesis in preneoplastic stages [9]. This evidence concerns the gene ERBB2 and pancreatic neoplasm.